Comparison · NCT03710603-sae
Velcade Lenalidomide Dexamethasone (VRd) vs Daratumumab + VRd (D-VRd): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Velcade Lenalidomide Dexamethasone (VRd) vs Daratumumab + VRd (D-VRd): serious adverse events. Trial comparisons, record NCT03710603-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03710603-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.493 | 0.441 | 0.545 | wilson | |
| Risk in group 2 | 0.57 | 0.518 | 0.621 | wilson | |
| Risk difference, group 1 minus group 2 | -0.077 | -0.15 | -0.00299 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.865 | 0.752 | 0.995 | log | |
| Odds ratio, group 1 over group 2 | 0.734 | 0.544 | 0.988 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Velcade Lenalidomide Dexamethasone (VRd) than on Daratumumab + VRd (D-VRd) | 13 | 6.67 | 334 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Velcade Lenalidomide Dexamethasone (VRd) | Arm A: Patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation were treated with bortezomib, lenalidomide, and dexamethasone for induction and consolidation followed by lenalidomide maintenance in 28-day cycles. After 4 cycles of induction, patients received high dose therapy with autologous stem cell transplantation. | 171 | 347 | EG000 |
| Group 2 | Daratumumab + VRd (D-VRd) | Arm B: Patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation were treated with subcutaneous daratumumab in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation followed by subcutaneous daratumumab in combination with lenalidomide maintenance in 28-day cycles. After 4 cycles of induction, patients received high dose therapy with autologous stem cell transplantation. | 200 | 351 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- AEs that started during the treatment until 30 days after the last dose of study treatment. Maximum follow up was 54.41 months.
Source ClinicalTrials.gov
Trial
- Title
- Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
- NCT number
- NCT03710603
- Phases
- PHASE3
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Velcade, Lenalidomide, dexamethasone
- Lead sponsor
- Stichting European Myeloma Network
- Results first posted
- 2024-12-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03710603?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03710603-sae